Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. Its lead clinical candidate is STK-001, which is in phase I/IIa clinical trial to treat Dravet syndrome, a severe and progressive genetic epilepsy; and STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. It had entered into a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.

Stoke Therapeutics, Inc.

Stoke Therapeutics develops RNA-based therapies aimed at restoring protein expression to address genetic diseases, focusing on conditions like Dravet syndrome and autosomal dominant optic atrophy (ADOA).

Stoke Therapeutics

Stoke Therapeutics | 12,841 followers on LinkedIn. Stoke Therapeutics (Nasdaq: STOK), is a biotechnology company dedicated to addressing the underlying cause of severe diseases. The company is pursuing an entirely new approach to treating severe diseases. We are initially focused on diseases of the central nervous system and the eye, with an emphasis on haploinsufficiencies, which are diseases caused by a loss of about half of the normal protein function.

Chief Financial Officer (CFO)

Stephen Tulipano

SVP and Head of Clinical Development Operations

Marissa V.

Vice President Quality Assurance

Samuel Manoranjan

Lynne Weston

Celebrating #Diwali is a beloved tradition at Stoke. As the Festival of Lights, our team looks forward to celebrating together every year with lights, food, and a sense of community. This meaningful holiday symbolizes renewal, unity, and togetherness – all values that resonate deeply within our team. #StokedAboutStoke

We’re proud to support Biomedical Science Careers Program (BSCP) ’s Evening of Hope, an event dedicated to advancing opportunities for underrepresented minorities and inspiring future leaders in biomedical sciences. The work of BSCP in fostering diversity and inclusion is critical in shaping the future of healthcare. We’re honored to support their important mission. Together, we can continue to break down barriers and create pathways for the next generation of experts in science and medicine. #BSCP #eveningofhope2024

Today on #SUDEPActionDay2024 , we’re raising awareness about Sudden Unexpected Death in Epilepsy (SUDEP) and the importance of understanding this serious risk. Raising awareness about the risks associated with epilepsy is essential. Taking an active role in discussing, reviewing, and reducing these risks helps ensure that those affected by epilepsy can live safer and healthier lives. We stand with the epilepsy community and support families navigating these challenges. Learn more and get involved: https://lnkd.in/em8nkZy #SUDEP #OurRisksOurRights

I'm elated to share that our manuscript titled “Antisense Oligonucleotide STK-002 Increases OPA1 in Retina and Improves Mitochondrial Function in Autosomal Dominant Optic Atrophy Cells” was recently accepted for publication in Nucleic Acid Therapeutics and is now available online! https://lnkd.in/etXWiw4t This study presents preclinical data that support the progression of STK-002 towards the clinic as the first potential disease-modifying treatment for autosomal dominant optic atrophy (ADOA), an inherited disease that often leads to blindness and currently has no treatment. A heartfelt thank you to my amazing colleagues and mentors at Stoke Therapeutics who contributed their time, expertise, and passion to this project. Your dedication and collaboration were invaluable and made this accomplishment possible. Reflecting on this journey, I’m reminded of how fulfilling and satisfying it is to engage in research that not only pushes the boundaries of knowledge but also holds the potential to make a difference in the lives of patients suffering from severe genetic diseases. It’s a powerful reminder of why we do what we do at Stoke! #oligonucleotide #antisense #RNA #ADOA #OPA1 #biotech

Aditya Venkatesh

Today, Stoke announced highlights from presentations at the 15th European Epilepsy Congress related to the Company’s work to develop the first disease-modifying medicine for #Dravetsyndrome . Learn more in our press release: https://lnkd.in/dxKt8Pbm #ILAE #EEC2024 International League Against Epilepsy

Stoke is pleased to announce the appointment of Eric Olson as Chief Business Officer. Mr. Olson brings two decades of successful corporate business development experience with an emphasis on #rarediseases and #RNA therapeutics https://lnkd.in/eT4Nk7bv

Today we announced upcoming investor conference presentations at H.C. Wainwright & Co., LLC ’s 26th Annual Global Investment Conference and Cantor Fitzgerald ’s 2024 Global Healthcare Conference. Learn more: https://lnkd.in/d8bErxUj #CantorHCC #Biotech #innovation #investment

The Stoke team is heading to the International League Against Epilepsy's 15th European #Epilepsy Congress in Rome! We look forward to sharing encore data from our #Dravetsyndrome clinical program. Learn more about our upcoming presentations: https://lnkd.in/eWNxNQGC #EEC2024 #ILAE

#ICYMI Our co-founder Isabel Aznarez discussed how her early research in human genetics inspired her and put her on the path to dedicate her life to science. Learn more about Isabel’s background, what led her to start Stoke, and the work her team is doing to target the underlying cause of severe diseases with a unique RNA-based approach. #StokedAboutStoke #RNA #biotech #innovation BiotechTV , Brad Loncar

Our CEO Edward M. Kaye, MD sat down with Brad Loncar of BiotechTV to discuss why he’s so excited to be leading Stoke in our mission to change the way severe diseases are treated by upregulating protein expression with #RNA -based medicines. #StokedAboutStoke #biotech #leadership

	Dec '17	Dec '18	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
revenue						12.40M -	8.78M 29.22%
cost of revenue
gross profit						12.40M -	8.78M 29.22%
selling and marketing expenses
general and administrative expenses	1.96M -	4.41M 125.46%	11.91M 170.16%	20.85M 74.98%	31.90M 53.01%	38.92M 22.03%	41.32M 6.16%
selling general and administrative expenses	1.96M -	4.41M 125.46%	11.91M 170.16%	20.85M 74.98%	31.90M 53.01%	38.92M 22.03%	41.32M 6.16%
research and development expenses	3.60M -	8.37M 132.66%	23.76M 183.88%	32.20M 35.49%	54.17M 68.24%	77.84M 43.70%	82.23M 5.65%
other expenses	-4K -	-10K 150%	2K 120%	57K 2,750%	140K 145.61%	167K 19.29%
cost and expenses	5.55M -	12.78M 130.12%	35.68M 179.15%	53.04M 48.67%	86.06M 62.25%	116.76M 35.67%	123.55M 5.82%
operating expenses	5.55M -	12.78M 130.12%	35.68M 179.15%	53.04M 48.67%	86.06M 62.25%	116.76M 35.67%	123.55M 5.82%
interest expense					120K -	3.12M 2,501.67%	9.91M 217.36%
ebitda	-5.44M -	-12.57M 130.97%	-35.68M 183.90%	-53.04M 48.67%	-86.06M 62.25%	-104.36M 21.25%	-114.77M 9.98%
operating income	-5.55M -	-12.78M 130.12%	-35.68M 179.15%	-53.04M 48.67%	-86.06M 62.25%	-104.36M 21.25%	-114.77M 9.98%
depreciation and amortization	113K -	214K 89.38%	450K 110.28%	888K 97.33%	974K 9.68%	1.55M 58.73%
total other income expenses net	-4K -	-10K 150%	3.35M 33,630%	801K 76.11%	260K 67.54%	3.29M 1,165%	10.07M 206.29%
income before tax	-5.56M -	-12.52M 125.28%	-32.33M 158.17%	-52.24M 61.62%	-85.81M 64.24%	-101.07M 17.79%	-104.70M 3.59%
income tax expense		260K -	-3.80M 1,561.92%	-1.63M 57.06%	-1.09M 32.97%	-7.96M 627.33%
net income	-5.56M -	-12.52M 125.28%	-28.52M 127.81%	-50.61M 77.43%	-84.71M 67.38%	-93.11M 9.91%	-104.70M 12.45%
weighted average shs out	12.79M -	23.51M 83.90%	17.97M 23.56%	33.49M 86.34%	36.74M 9.71%	38.90M 5.87%	43.99B 113,004.77%
weighted average shs out dil	12.79M -	23.51M 83.90%	17.97M 23.56%	33.49M 86.34%	36.74M 9.71%	38.90M 5.87%	43.99B 113,004.77%
eps	-0.43 -	-0.53 23.26%	-1.59 200%	-1.51 5.03%	-2.31 52.98%	-2.39 3.46%	-0.00 99.90%
epsdiluted	-0.43 -	-0.53 23.26%	-1.59 200%	-1.51 5.03%	-2.31 52.98%	-2.39 3.46%	-0.00 99.90%

COM:STOKETHERAPEUTICS

Stoke Therapeutics

Last Close

11.27

22/11 21:00

Market Cap

691.12M

Beta: -

Volume Today

240.61K

Avg: -

Preview